{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T19:32:39Z","timestamp":1793388759910,"version":"4.5.0"},"reference-count":25,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,12,28]],"date-time":"2024-12-28T00:00:00Z","timestamp":1735344000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2024,12,28]],"date-time":"2024-12-28T00:00:00Z","timestamp":1735344000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"Biomedical Research Institute Grant Pusan National University Hospital","award":["202400620001"],"award-info":[{"award-number":["202400620001"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"DOI":"10.1038\/s41598-024-83321-7","type":"journal-article","created":{"date-parts":[[2024,12,28]],"date-time":"2024-12-28T08:49:17Z","timestamp":1735375757000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["Long-term use of proton pump inhibitors was associated with rapid progression to end stage kidney disease in a Korean nationwide study"],"prefix":"10.1038","volume":"14","author":[{"given":"Yu Jeong","family":"Lee","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jinmi","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dong Han","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nam Kyung","family":"Je","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Harin","family":"Rhee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,12,28]]},"reference":[{"key":"83321_CR1","doi-asserted-by":"publisher","first-page":"1159","DOI":"10.1007\/s00228-023-03534-z","volume":"79","author":"LGT Shanika","year":"2023","unstructured":"Shanika, L. G. T., Reynolds, A., Pattison, S. & Braund, R. Proton pump inhibitor use: Systematic review of global trends and practices. Eur. J. Clin. Pharmacol. 79, 1159\u20131172 (2023).","journal-title":"Eur. J. Clin. Pharmacol."},{"key":"83321_CR2","unstructured":"NICE Guideline cg184. 2019 Surveillance of Gastro-Oesophageal Reflux Disease and Dyspepsia in Adults: Investigation and Management (2019)."},{"key":"83321_CR3","unstructured":"Statista. Leading chemical substances dispensed in England in 2022. https:\/\/www.statista.com\/statistics\/378445\/prescription-cost-analysis-top-twenty-chemicals-by-items-in-england\/."},{"key":"83321_CR4","unstructured":"ClinCalc, L. L. C. Drug usage statistics, United States (2013\u20132021). https:\/\/clincalc.com\/DrugStats\/Drugs\/Omeprazole."},{"key":"83321_CR5","doi-asserted-by":"publisher","first-page":"276","DOI":"10.17480\/psk.2021.65.4.276","volume":"65","author":"J-A Oh","year":"2021","unstructured":"Oh, J.-A., Lee, G.-M., Chung, S.-Y., Cho, Y.-S. & Lee, H.-J. Utilization trends of proton pump inhibitors in South Korea: Analysis using 2016\u20132020 Healthcare Bigdata Hub by Health Insurance Review and Assessment Service. Yakhak Hoeji 65, 276\u2013283 (2021).","journal-title":"Yakhak Hoeji"},{"key":"83321_CR6","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1016\/j.therap.2020.06.019","volume":"76","author":"A Koyyada","year":"2021","unstructured":"Koyyada, A. Long-term use of proton pump inhibitors as a risk factor for various adverse manifestations. Therapie 76, 13\u201321 (2021).","journal-title":"Therapie"},{"key":"83321_CR7","doi-asserted-by":"publisher","first-page":"497","DOI":"10.1053\/j.ajkd.2019.07.012","volume":"75","author":"Z Al-Aly","year":"2020","unstructured":"Al-Aly, Z., Maddukuri, G. & Xie, Y. Proton pump inhibitors and the kidney: Implications of current evidence for clinical practice and when and how to deprescribe. Am. J. Kidney Dis. 75, 497\u2013507 (2020).","journal-title":"Am. J. Kidney Dis."},{"key":"83321_CR8","doi-asserted-by":"publisher","first-page":"238","DOI":"10.1001\/jamainternmed.2015.7193","volume":"176","author":"B Lazarus","year":"2016","unstructured":"Lazarus, B. et al. Proton pump inhibitor use and the risk of chronic kidney disease. JAMA Intern. Med. 176, 238\u2013246 (2016).","journal-title":"JAMA Intern. Med."},{"key":"83321_CR9","doi-asserted-by":"publisher","first-page":"112","DOI":"10.1186\/s12882-016-0325-4","volume":"17","author":"P Arora","year":"2016","unstructured":"Arora, P. et al. Proton pump inhibitors are associated with increased risk of development of chronic kidney disease. BMC Nephrol. 17, 112 (2016).","journal-title":"BMC Nephrol."},{"key":"83321_CR10","doi-asserted-by":"publisher","first-page":"3153","DOI":"10.1681\/ASN.2015121377","volume":"27","author":"Y Xie","year":"2016","unstructured":"Xie, Y. et al. Proton pump inhibitors and risk of incident CKD and progression to ESRD. J. Am. Soc. Nephrol. 27, 3153\u20133163 (2016).","journal-title":"J. Am. Soc. Nephrol."},{"key":"83321_CR11","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000003363","volume":"95","author":"YC Peng","year":"2016","unstructured":"Peng, Y. C. et al. Association between the use of proton pump inhibitors and the risk of ESRD in renal diseases: A population-based, case-control study. Med. (Baltim). 95, e3363 (2016).","journal-title":"Med. (Baltim)."},{"key":"83321_CR12","doi-asserted-by":"publisher","first-page":"702","DOI":"10.1053\/j.gastro.2017.05.046","volume":"153","author":"DCF Klatte","year":"2017","unstructured":"Klatte, D. C. F. et al. Association between proton pump inhibitor use and risk of progression of chronic kidney disease. Gastroenterology 153, 702\u2013710 (2017).","journal-title":"Gastroenterology"},{"key":"83321_CR13","unstructured":"World Health Organization. The top 10 causes of death. https:\/\/www.who.int\/news-room\/fact-sheets\/detail\/the-top-10-causes-of-death."},{"key":"83321_CR14","doi-asserted-by":"publisher","first-page":"8","DOI":"10.23876\/j.krcp.23.232","volume":"43","author":"DH Kim","year":"2024","unstructured":"Kim, D. H. et al. Kidney Health Plan 2033 in Korea: Bridging the gap between the present and the future. Kidney Res. Clin. Pract. 43, 8\u201319 (2024).","journal-title":"Kidney Res. Clin. Pract."},{"key":"83321_CR15","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0207561","volume":"13","author":"HJ Lee","year":"2018","unstructured":"Lee, H. J. et al. Correction: Chronic kidney disease (CKD) patients are exposed to more proton pump inhibitor (PPI)s compared to non-CKD patients. PLOS One 13, e0207561 (2018).","journal-title":"PLOS One"},{"key":"83321_CR16","doi-asserted-by":"publisher","first-page":"835","DOI":"10.1093\/qjmed\/hcz166","volume":"112","author":"CH Grant","year":"2019","unstructured":"Grant, C. H. et al. Proton pump inhibitor use and progression to major adverse renal events: A competing risk analysis. Q. J. M. 112, 835\u2013840 (2019).","journal-title":"Q. J. M."},{"key":"83321_CR17","doi-asserted-by":"publisher","first-page":"264","DOI":"10.1186\/s12882-021-02449-0","volume":"22","author":"L Cholin","year":"2021","unstructured":"Cholin, L. et al. Proton-pump inhibitor vs. H2-receptor blocker use and overall risk of CKD progression. BMC Nephrol. 22, 264 (2021).","journal-title":"BMC Nephrol."},{"key":"83321_CR18","doi-asserted-by":"publisher","first-page":"2967","DOI":"10.1111\/bcp.14713","volume":"87","author":"S Liabeuf","year":"2021","unstructured":"Liabeuf, S. et al. Adverse outcomes of proton pump inhibitors in patients with chronic kidney disease: The CKD-REIN cohort study. Br. J. Clin. Pharmacol. 87, 2967\u20132976 (2021).","journal-title":"Br. J. Clin. Pharmacol."},{"key":"83321_CR19","doi-asserted-by":"publisher","first-page":"674","DOI":"10.1038\/s41597-023-02580-7","volume":"10","author":"JW Kim","year":"2023","unstructured":"Kim, J. W. et al. Scalable infrastructure supporting reproducible nationwide healthcare data analysis toward FAIR stewardship. Sci. Data 10, 674 (2023).","journal-title":"Sci. Data"},{"key":"83321_CR20","doi-asserted-by":"publisher","first-page":"103","DOI":"10.12997\/jla.2022.11.2.103","volume":"11","author":"DS Kyoung","year":"2022","unstructured":"Kyoung, D. S. & Kim, H. S. Understanding and utilizing claim data from the Korean National Health Insurance Service (NHIS) and Health Insurance Review & Assessment (HIRA) database for research. J. Lipid Atheroscler. 11, 103\u2013110 (2022).","journal-title":"J. Lipid Atheroscler."},{"key":"83321_CR21","first-page":"966","volume":"310","author":"M Schuemie","year":"2024","unstructured":"Schuemie, M. et al. Health-analytics data to evidence suite (HADES): Open-source software for observational research. Stud. Health Technol. Inform. 310, 966\u2013970 (2024).","journal-title":"Stud. Health Technol. Inform."},{"key":"83321_CR22","doi-asserted-by":"publisher","first-page":"558","DOI":"10.1053\/j.ajkd.2014.04.027","volume":"64","author":"AK Muriithi","year":"2014","unstructured":"Muriithi, A. K. et al. Biopsy-proven acute interstitial nephritis, 1993\u20132011: A case series. Am. J. Kidney Dis. 64, 558\u2013566 (2014).","journal-title":"Am. J. Kidney Dis."},{"key":"83321_CR23","doi-asserted-by":"publisher","first-page":"E166","DOI":"10.9778\/cmajo.20140074","volume":"3","author":"T Antoniou","year":"2015","unstructured":"Antoniou, T. et al. Proton pump inhibitors and the risk of acute kidney injury in older patients: A population-based cohort study. CMAJ Open 3, E166\u2013E171 (2015).","journal-title":"CMAJ Open"},{"key":"83321_CR24","doi-asserted-by":"publisher","first-page":"1436","DOI":"10.1056\/NEJMoa2024816","volume":"383","author":"HJL Heerspink","year":"2020","unstructured":"Heerspink, H. J. L. et al. Dapagliflozin in patients with chronic kidney disease. N. Engl. J. Med. 383, 1436\u20131446 (2020).","journal-title":"N. Engl. J. Med."},{"key":"83321_CR25","doi-asserted-by":"crossref","unstructured":"The EMPA-KIDNEY Collaborative Group et al. Empagliflozin in patients with chronic kidney disease. N. Engl. J. Med. 388, 117\u2013127 (2023).","DOI":"10.1056\/NEJMoa2204233"}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-024-83321-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-024-83321-7","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-024-83321-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,12,28]],"date-time":"2024-12-28T23:05:21Z","timestamp":1735427121000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-024-83321-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,12,28]]},"references-count":25,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["83321"],"URL":"https:\/\/doi.org\/10.1038\/s41598-024-83321-7","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,12,28]]},"assertion":[{"value":"3 July 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 December 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 December 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"Approval to perform the analyses was obtained with a waiver of informed consent from the Pusan National University IRB Committee [PNUH IRB 2308-021-130].","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}}],"article-number":"31477"}}